Composite International Diagnostic Interview (CIDI) - Subject Follow-up

This measure appears in the following time-points: Follow72.

Related Construct

Mental Health

Description of Measure

The Composite International Diagnostic Interview (CIDI; World Health Organization, 1990) is a comprehensive, fully structured interview used to assess mental disorders. By means of computerized algorithms, the CIDI provides both lifetime ("Ever") and current ("Past year" & "Past 30 days") diagnosis as defined by the DSM-IV and ICD-10. The entire CIDI was not administered. The following eight modules were selected for the purpose of this study: Major Depressive Disorder, Dysthymia, Manic Episode, Posttraumatic Stress Disorder, Alcohol Abuse, Alcohol Dependence, Drug Abuse, & Drug Dependence. During the interview, all participants' are asked questions about selective symptoms of psychiatric disorders. Based on predetermined skip patterns, positive responses to these screening items are followed by more detailed questions to determine if the endorsed symptom is a psychiatric symptom and is not due to medication, drugs, alcohol or to a physical illness or injury. If symptoms are endorsed and occur in a pattern which suggests a diagnosis might be present, additional questions are asked to establish the onset and recency of the symptoms.

The CIDI was initially administered to Pathways Study participants at the time of the baseline interview. However, because psychiatric diagnosis may emerge in later adolescence/early adulthood, we administered the CIDI a second time. The second administration of the CIDI occurred between the 72 and 84month. Interviewers were given the flexibility to choose a time to administer the CIDI because doing it in one session (at the same time as the follow-up interview) would make for a session that was too long to maintain maximum subject engagement. Due to these circumstances, we provide three variables that indicate the timing of the CIDI interview. This is important information to have when integrating follow-up data with the CIDI data. These variables are:

The date of the CIDI interview [S9Date72]
The linear month number corresponding to the CIDI interview date [S9InLMo72]
The closest recall period month number (s#m#) to the CIDI interview date [S9Cls_Rdinrpmo72]

All diagnostic scoring algorithms used by the Pathways study are from Ron Kessler at Harvard University.

The following variables are available:

A variable indicating the interview version in which the CIDI was completed [S9CIDI_QVersion]
Marker for cases meeting diagnostic criteria for Major Depressive Disorder over the lifetime [S9mdd]
Marker for cases meeting diagnostic criteria for Major Depressive Disorder over the past year [S9mdd12]
Marker for cases meeting diagnostic criteria for Major Depressive Disorder over the past 30 days [S9mdd30]
Marker for cases meeting diagnostic criteria for Dysthymia over the lifetime [S9dys]
Marker for cases meeting diagnostic criteria for Dysthymia over the past year [S9dys12]
Marker for cases meeting diagnostic criteria for Dysthymia over the past 30 days [S9dys30]
Marker for cases meeting diagnostic criteria for Mania over the lifetime [S9mania]
Marker for cases meeting diagnostic criteria for Mania over the past year [S9mania12]
Marker for cases meeting diagnostic criteria for Mania over the past 30 days [S9mania30]
Marker for cases meeting diagnostic criteria for Posttraumatic Stress Disorder over the lifetime [S9ptsd]
Marker for cases meeting diagnostic criteria for Posttraumatic Stress Disorder over the past year [S9ptsd12]
Marker for cases meeting diagnostic criteria for Posttraumatic Stress Disorder over the past 30 days [S9ptsd30]
Marker for cases meeting diagnostic criteria for Alcohol Abuse over the lifetime [S9alchabu]
Marker for cases meeting diagnostic criteria for Alcohol Abuse over the past year [S9alcabu12]
Marker for cases meeting diagnostic criteria for Alcohol Abuse over the past 30 days [S9alcabu30]
Marker for cases meeting diagnostic criteria for Alcohol Dependence over the lifetime [S9alchdep]
Marker for cases meeting diagnostic criteria for Alcohol Dependence over the past year [S9alcdep12]
Marker for cases meeting diagnostic criteria for Alcohol Dependence over the past 30 days [S9alcdep30]
Marker for cases meeting diagnostic criteria for Drug Abuse over the lifetime [S9drugabu]
Marker for cases meeting diagnostic criteria for Drug Abuse over the past year [S9druabu12]
Marker for cases meeting diagnostic criteria for Drug Abuse over the past 30 days [S9druabu30]
Marker for cases meeting diagnostic criteria for Drug Dependence over the lifetime [S9drugdep]
Marker for cases meeting diagnostic criteria for Drug Dependence over the past year [S9drudep12]
Marker for cases meeting diagnostic criteria for Drug Dependence over the past 30 days [S9drudep30]

In addition, we created the following symptoms counts:

Count of Major Depression symptoms that were EVER present [S9MDsymcnt]
Count of PTSD symptoms that were EVER present [S9PTSDsymcnt]

Data Issues

At the baseline interview, the Pathways study used two slightly different versions of the CIDI secondary to changes implemented by the CIDI authors at Harvard. These changes had important implications for the generation of a diagnosis (see the baseline CIDI codebook 'Data Issues' section for more specific information).

These issues were no longer present when the CIDI was administered at the 72-month interview.

References

Kessler, R.C., Ustun, T.B. (2004). The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). International Journal of Methods in Psychiatric Research, 13 (2), 93-121.
World Health Organization. (1990). Composite International Diagnostic Interview. Geneva, Switzerland, World Health Organization.
Kessler, R.C., McGonagle, K.A., Zhao, S., and Nelson, C.B., et al. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Archives of General Psychiatry, 51 (1), 8-19.